Panacea Biotec announces completion of tenure of Director Narotam Kumar Juneja
The company confirms the conclusion of Narotam Kumar Juneja’s tenure as Non-Executive Non-Independent Director and Whole-Time Director at Panacea Biotec
Panacea Biotec has announced that Narotam Kumar Juneja has completed his tenure as a Non-Executive Non-Independent Director of the company as of March 31, 2025. His term was set during the Annual General Meeting (AGM) held on September 27, 2024, where he was reappointed as a director liable to retire by rotation until March 31, 2025.
Following the completion of his tenure, Juneja has also ceased to be the Chairperson and a member of the Committees of the Board of Directors of Panacea Biotec. Additionally, he has concluded his role as a Whole-Time Director at Panacea Biotec’s material subsidiary, Panacea Biotec, effective the same date.
The Board of Directors and the management of Panacea Biotec have expressed appreciation for Juneja’s contributions and guidance toward the company’s business growth during his tenure.